linagliptin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 31 Diseases   34 Trials   34 Trials   1690 News 
40 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linagliptin / Generic mfg.
ACTRN12615000732583: Stop or Replace: Effect of stopping sulfonylureas or replacing sulfonylureas with a dipeptidyl peptidase 4 (DPP-IV) inhibitor in Type 2 diabetes patients on pre-mix insulin.

Not yet recruiting
4
99
 
St Vincent's Hospital Sydney, St Vincent's Hospital Sydney, Competitive Grant from Regional Diabetes Support Scheme, Novo Nordisk
type 2 diabetes
 
 
ChiCTR-IPR-15006340: Renal effects of Saxagliptin and Linagliptin in diabetic nephropathy: A randomized, double-blind, head to head study.

Not yet recruiting
4
74
 
with Saxagliptin treatment ;with Linagliptin treatment
Tianjin Medical University; Level of the institution:, The National Natural Science General Program
Diabetic Nephropathy
 
 
2013-000330-35: The impact on the blood sugar lowering drug Linagliptin and blood vessel function in patients with type 2 diabetes Der Einfluss der blutzuckersenkenden Substanz Linagliptin auf die Blutgefäßfunktion bei Patienten mit Typ 2 Diabetes

Ongoing
4
50
Europe
Trajenta (Linagliptin), Trajenta (Linagliptin)
Medizinische Universität Graz, Boehringer Ingelheim RCV GmbH & Co KG
Diabetes mellitus Type 2 Diabetes mellitus Typ 2
 
 
2015-002309-12: To compare gliclazide with linagliptin on the frequency of hypoglycaemia among patients with type II diabetes and chronic kidney disease stage 3b and 4.

Ongoing
4
50
Europe
Linagliptin, Gliclazide, Linagliptin, gliclazide, Linagliptin, gliclazide
Imperial College London, Joint Research Compliance Office, Boehringer Ingelheim Ltd.
Diabetes Mellitus and chronic kidney disease
 
 
2015-005113-73: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
52
Europe
Tablet, Capsule, Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, UMCG
Type 2 diabetes with albuminuria, Type 2 diabetes with albumin in urine., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2015-005691-26: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, University Medical Center Groningen
Type 1 diabetes with albuminuria, Type 1 diabetes with albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2017-001977-18: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Olumiant
University Medical Center Groningen, University Medical Center Groningen
Type 2 diabetes and albuminuria, Type 2 diabetes and albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2017-004406-18: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4inhibitors or glinides: focus on pro-inflammatory and oxidative stressmarkers (GOOD-WP1) Outcomes geriatrici in pazienti anziani affetti da diabete di tipo 2 trattaticon gli inibitori DPP4 o le glinidi: focus sui marcatori pro-infiammatori e distress ossidativo.

Not yet recruiting
4
126
Europe
TRAJENTA, Film-coated tablet, Tablet, TRAJENTA
IRCC INRCA, MINISTRY OF HEALTH
TYPE 2 DIABETES DIABETE DI TIPO 2, TYPE 2 DIABETES DIABETE DI TIPO 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2017-004663-12: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on cognitive functioning (GOOD-WP3) Outcomes geriatrici in pazienti anziani affetti da diabete di tipo 2 trattati con gli inibitori DPP4 o le glinidi: focus sulla funzione cognitiva

Not yet recruiting
4
146
Europe
Novonorm, Trajenta, [NA], Tablet, Film-coated tablet, NOVONORM - 0.5 MG COMPRESSE-30 COMRESSE IN BLISTER, TRAJENTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 28 COMPRESSE
A.O.U. Università degli Studi della Campania "Luigi Vanvitelli", Ministero della Salute - Bando ricerca finalizzata - Italia
type 2 diabetes mellitus Diabete mellito di tipo 2, type 2 diabetes mellitus Diabete mellito di tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR-IPR-17010537: Linagliptin treating diabetes after liver transplantion

Not yet recruiting
4
100
 
Linagliptin ;HumalogMix50
The General Hospital of Chinese People's Armed Police Forces; The General Hospital of Chinese People's Armed Police Forces, Self-financing
transplant recipient, diabetes
 
 
2018-000359-42: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on sarcopenia markers of muscle and physical performance status (GOOD-WP2) Outcome geriatrici in pazienti anziani affetti da diabete mellito tipo 2 trattati con inibitori DPP-4 o glinidi: focus sugli indicatori muscolari di sarcopenia e sullo stato di performance fisica (GOOD-WP2)

Not yet recruiting
4
180
Europe
Repaglinide, LINAGLIPTIN, [a10bx02], [a10bh05], Tablet, Film-coated tablet, NovoNorm 0,5mg, Trajenta 5mg
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute
Elderly patients suffering from type 2 diabetes mellitus in treatment with metformina Pazienti anziani affetti da diabete mellito di tipo 2 in terapia con metformina, Elderly patient suffering from type 2 diabetes mellitus Pazienti anziani affetti da diabete mellito di tipo 2, Diseases [C] - Hormonal diseases [C19]
 
 
NCT05200793: Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Recruiting
4
75
RoW
Empagliflozin 25 mg, Empagliflozin, Linagliptin 10 mg, Linagliptin, Metformin 1500 mg, Metformin
Alexandria University
Polycystic Ovary Syndrome (PCOS)
07/22
09/22
ChiCTR2000035887: A Randomized controlled trial for liraglutide plus linagliptin in improving neurological function of patients with acute ischemic stroke and hyperglycemia

Not yet recruiting
4
680
 
Liraglutide plus Liraglutide ;Standard hypoglycemic therapy
Shanghai 6th People's Hospital; Shanghai 6th People's Hospital, Shanghai Shenkang Hospital Development Center
acute ischemic stroke
 
 
NCT03194945: Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Completed
4
412
RoW
CSII followed by Lina+MET, CSII+Lina+Met, CSII followed by Lina, CSII+Lina, CSII followed by MET, CSII+Met, CSII alone, CSII
Sun Yat-sen University, The Seventh Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Dongguan People's Hospital, Clifford Hospital, Guangzhou Panyu Central Hospital, Nanfang Hospital, Southern Medical University, Chinese PLA General Hospital, Peking University People's Hospital, Shanghai 10th People's Hospital, Shanghai Changzheng Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Huizhou Municipal Central Hospital
Type 2 Diabetes Mellitus
12/22
12/22
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 
ChiCTR2100049856: Effect and mechanism of polyethylene glycol Losenazeptide on cardiac microangiopathy in patients with type 2 diabetes mellitus complicated with massive albuminuria

Not yet recruiting
4
100
 
Polyethylene Glycol Loxenatide injection ;Linagliptin Tablets
Tianjin Medical University Chu Hsien-l Memorial Hospital; Tianjin Medical University Chu Hsien-l Memorial Hospital, China International Medical Foundation Special Fund for International Diabetes Exchange and Practice “SenMei China Diabetes Research Fund”
type 2 diabetes mellitus
 
 
HHTN, NCT06449833: Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Recruiting
4
100
RoW
Henagliflozein and Metformin, Linagliptin and Metformin
Zhujiang Hospital
Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
11/26
11/26
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting
4
938
RoW
Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd.
Type2diabetes
04/25
06/25
SEMA-VR, NCT05870462: Semaglutide and Vascular Regeneration

Recruiting
4
100
Canada
Semaglutide Pen Injector, Ozempic, Wegovy
Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada
Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
12/24
12/24
NCT06851962: Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial

Not yet recruiting
4
504
Europe
Metformin, Dulaglutide, Semaglutide 1.0 mg, Empagliflozin (BI 10773), Canagliflozin, Dapagliflozin, pioglitazone, Sitagliptin, Vildagliptin (Galvus), linagliptin
Fundación para la Investigación del Hospital Clínico de Valencia
Diabetes Mellitus Type 2
06/26
07/26
ChiCTR2400089745: The efiicacy and safety of biweekly cofrogliptin versus daily linagliptin as add-on in Patients with Type 2 Diabetes Inadequately Controlled by Dual Therapy(metformin and dapagliflozin): A Multicenter, Randomized, Open-Label, Active-Controlled,non-inferiority trial

Not yet recruiting
4
170
 
Triple combination therapy with cofrogliptin added to metformin and SGLT2i in type 2 diabetes mellitus (T2DM) patients who have inadequately controlled blood glucose despite adequate metformin and SGLT2i therapy for at least 12 weeks.; Triple combination therapy with linagliptin as active-control drug added to metformin and SGLT2i in type 2 diabetes mellitus (T2DM) patients who have inadequately controlled blood glucose despite adequate metformin and SGLT2i therapy for at least 12 weeks.
Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology; Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology, Haisco Pharmaceutical Group Co.,Ltd
Type 2 Diabetes Mellitus
 
 
2013-000418-39: Early Prevention of Diabetes Complications in people with Pre-Diabetes in Europe Prevención temprana de complicaciones por diabetes en personas con pre-diabetes en Europa Wczesne zapobieganie powikłaniom cukrzycy u osób z tzw. stanem przedcukrzycowym w Europie

Ongoing
3
2400
Europe
GLUCOPHAGE/GLUCOPHAGE FORTE/DIANBEN/RISIDON 850mg film-coated tablet, Gluocophage 850 mg film-coated tablets, Trajenta 5 mg film-coated tablets, Jentadueto 2.5 mg/850 mg film-coated tablets, Gluocophage 850 mg film-coated tablets, Trajenta 5 mg film-coated tablets, Jentadueto 2.5 mg/850 mg film-coated tablets
FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES, FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES CARDIOVASCULARES (FIRCAVA), European Commission FP7
Non diabetic hyperglycaemia:Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) or both Hiperglucemia No Diabética:Intolerancia la Glucosa (ITG), Glucosa en ayuno alterada (GAA) o ambas
 
 
NCT05641337: Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Recruiting
3
184
RoW
Insulin Degludec and Insulin Aspart, metformin, linagliptin
Huashan Hospital
Liver Cirrhosis, Diabetes
12/25
12/25
DÁLIA, NCT05886088: Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Not yet recruiting
3
597
RoW
LID104, Dapagliflozin, Linagliptin
EMS
Type 2 Diabetes Mellitus
05/26
01/27
2013-004333-33: Shockwave treatment for heart failure

Ongoing
2
94
Europe
Junuvia, Linagliptin, Teriparatide, Film-coated tablet, Solution for injection/infusion in pre-filled syringe, Januvia, Trajenta, Forsteo
Imperial College London
ischaemic cardiomyopathy, heart failure caused by heart attacks, Diseases [C] - Cardiovascular Diseases [C14]
 
 
DIASA3, NCT04662866: Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

Recruiting
2
64
Europe
Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg, biguanide, glitazone, sodium glucose transport inhibitor, dipeptidyl peptidase inhibitor
Oslo University Hospital, The Research Council of Norway, Norwegian Diabetes Association, South-Eastern Norway Regional Health Authority, University of Oslo, University Hospital, Akershus, Vestre Viken Hospital Trust, University of Glasgow
Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders
12/22
10/23
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
04/25
04/25
Morpheus Lung, NCT03337698 / 2017-001267-21: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Checkmark Combo atezolizumab
Nov 2017 - Nov 2017: Combo atezolizumab
Active, not recruiting
1/2
314
Europe, US, RoW
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
09/25
11/26
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Recruiting
1
34
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Recruiting
1
50
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT06243809: The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Not yet recruiting
1
48
NA
Linagliptin 5 mg Oral Tablet, Linagliptin, Trajenta 5 MG Oral Tablet
International Bio service
Healthy Volunteer
05/24
07/24
NCT05032001: ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

Enrolling by invitation
N/A
30
RoW
Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Metabolic Research Unit
Abdominal Obesity, Type 2 Diabetes
08/22
08/22
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
N/A
5
Europe
Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).
Erasme University Hospital
Type 2 Diabetes, Incretinomimetics, Pancreas
02/23
02/23
NCT05768945: Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Active, not recruiting
N/A
742670
US
Semaglutide, DPP-4 inhibitor
Brigham and Women's Hospital, National Institute on Aging (NIA), Rutgers University, Johns Hopkins University
Diabetes
07/23
12/23
NCT06570980: Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

Recruiting
N/A
200
RoW
sulfonylurease with metformin, DPP4 inhibitors with Metformin
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin
08/24
08/24
NCT05347459: Cognitive Protective Effect of Newer Antidiabetic Drugs

Recruiting
N/A
100
RoW
Dapagliflozin, Empagliflozin, Canagliflozin, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin
Alexandria University
Type 2 Diabetes
12/23
12/23
GIOIA, NCT03918148: Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes

Completed
N/A
1150
Europe
SGLT-2i, DPP-4i
University of Campania "Luigi Vanvitelli"
Type 2 Diabetes Mellitus
12/23
12/23
ON TARGET DM, NCT05073692: Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
N/A
270000
US
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute
Type 2 Diabetes Mellitus, Cardiovascular Diseases
12/24
08/25
BESTMED, NCT05161429: Observational Evaluation of Second Line Therapy Medications in Diabetes

Recruiting
N/A
550000
US
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, Baylor College of Medicine, Baylor Scott and White Research Institute, The Cleveland Clinic, HealthCore, Inc., Humana Inc., Massachusetts General Hospital, Medical Outcomes Management, University of Iowa, Allina Health, Intermountain Health Care, Inc., Marshfield Clinic, Medical College of Wisconsin, University of Missouri-Columbia, University of Utah
Diabetes Mellitus, Type 2
06/24
06/24
NCT04853615: SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Not yet recruiting
N/A
800
NA
Empagliflozin 25 MG, SGLT2 inhibitors
Fayoum University, Cairo University
SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
07/24
08/24

Download Options